MX340796B - Composiciones y procedimientos antigenicos del virus respiratorio sincitial. - Google Patents
Composiciones y procedimientos antigenicos del virus respiratorio sincitial.Info
- Publication number
- MX340796B MX340796B MX2012015030A MX2012015030A MX340796B MX 340796 B MX340796 B MX 340796B MX 2012015030 A MX2012015030 A MX 2012015030A MX 2012015030 A MX2012015030 A MX 2012015030A MX 340796 B MX340796 B MX 340796B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- respiratory syncytial
- syncytial virus
- antigenic compositions
- multilayer films
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 2
- 230000005875 antibody response Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36202910P | 2010-07-07 | 2010-07-07 | |
| US201161485669P | 2011-05-13 | 2011-05-13 | |
| PCT/US2011/043136 WO2012006395A1 (en) | 2010-07-07 | 2011-07-07 | Respiratory syncytial virus antigenic compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012015030A MX2012015030A (es) | 2013-06-13 |
| MX340796B true MX340796B (es) | 2016-07-27 |
Family
ID=45438747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012015030A MX340796B (es) | 2010-07-07 | 2011-07-07 | Composiciones y procedimientos antigenicos del virus respiratorio sincitial. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9487593B2 (https=) |
| EP (1) | EP2590675B1 (https=) |
| JP (1) | JP5890407B2 (https=) |
| CN (2) | CN103037898B (https=) |
| AU (1) | AU2011276251B2 (https=) |
| BR (1) | BR112013000345B1 (https=) |
| CA (1) | CA2799934C (https=) |
| DK (1) | DK2590675T3 (https=) |
| ES (1) | ES2688993T3 (https=) |
| IL (1) | IL222723B (https=) |
| MX (1) | MX340796B (https=) |
| RU (1) | RU2609661C2 (https=) |
| WO (1) | WO2012006395A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9433671B2 (en) | 2012-03-30 | 2016-09-06 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
| MY171498A (en) | 2012-08-01 | 2019-10-15 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| IL292567B2 (en) | 2013-08-13 | 2025-06-01 | Univ Northwestern | Peptide conjugated particles |
| WO2015183716A1 (en) | 2014-05-27 | 2015-12-03 | Artificial Cell Technologies, Inc. | Automated layer by layer construction of multilayer coated cores by tff |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2017048689A1 (en) | 2015-09-16 | 2017-03-23 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| US20170230649A1 (en) * | 2016-02-05 | 2017-08-10 | Qualcomm Incorporated | Calibration of hybrid auto focus (af) imaging systems |
| KR102774312B1 (ko) | 2017-04-04 | 2025-03-05 | 유니버시티 오브 워싱톤 | 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도 |
| CA3079604A1 (en) | 2017-10-13 | 2019-04-18 | Trellis Bioscience, Llc | Conformational epitopes in respiratory syncytial virus g protein central conserved region |
| CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| EP3833677A4 (en) | 2018-08-08 | 2022-04-27 | Trellis Bioscience, Inc. | IMPROVED RSV PASSIVE AND ACTIVE VACCINES |
| US20230414526A1 (en) * | 2022-03-29 | 2023-12-28 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2142817C1 (ru) * | 1993-08-06 | 1999-12-20 | Коннот Лабораториз Лимитед | Инактивированные вакцины респираторно-синцитиального вируса |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| ATE178906T1 (de) | 1994-08-25 | 1999-04-15 | Stichting Inst Dierhouderij | Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen |
| FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
| AUPO026596A0 (en) | 1996-06-05 | 1996-06-27 | Biomolecular Research Institute Limited | Viral peptide |
| DE60136381D1 (de) | 2000-10-18 | 2008-12-11 | Us Gov Health & Human Serv | Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| AUPR520201A0 (en) | 2001-05-23 | 2001-06-14 | Commonwealth Scientific And Industrial Research Organisation | Antiviral compounds |
| JP3997930B2 (ja) | 2003-02-27 | 2007-10-24 | 富士ゼロックス株式会社 | カーボンナノチューブの製造装置および製造方法 |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| US7615530B2 (en) | 2003-08-29 | 2009-11-10 | Artificial Cell Technologies, Inc. | Immunogenic compositions and methods of use |
| US7348399B2 (en) * | 2003-08-29 | 2008-03-25 | Louisiana Tech University Foundation, Inc. | Nanofabricated polypeptide multilayer films, coatings, and microcapsules |
| WO2006023029A2 (en) * | 2004-06-16 | 2006-03-02 | The Johns Hopkins University | The cysteine-rich region of respiratory syncytial virus and methods of use therefor |
| US20080131450A1 (en) | 2004-07-23 | 2008-06-05 | Pierre Fabre Medicament | Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions |
| US20080171070A1 (en) * | 2005-01-31 | 2008-07-17 | Pierre Schaaf | Polyelectrolyte Multilayer Film, Preparation And Uses Thereof |
| WO2006108226A1 (en) * | 2005-04-12 | 2006-10-19 | The University Of Queensland | Vaccine delivery system |
| CA2627376C (en) * | 2005-10-25 | 2016-07-05 | Donald Templeton Haynie | Immunogenic compositions and methods of use |
| EP1972348A1 (en) | 2007-03-14 | 2008-09-24 | Pierre Fabre Medicament | Novel vaccine composition for the treatment of respiratory infectious diseases |
| JP2010522540A (ja) | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
| US7723294B2 (en) * | 2007-04-02 | 2010-05-25 | Artificial Cell Technologies, Inc. | Polypeptide films and methods |
| WO2009079066A2 (en) * | 2007-09-26 | 2009-06-25 | Aparna Biosciences | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
| EP2058002A1 (en) * | 2007-10-31 | 2009-05-13 | Bestewil Holding B.V. | Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
| MX2011000668A (es) | 2008-07-18 | 2011-07-29 | Id Biomedical Corp Quebec | Antigenos quimericos polipeptidicos del virus sincitial respiratorio. |
| US20110318376A1 (en) | 2008-12-24 | 2011-12-29 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| US8846056B2 (en) | 2009-08-04 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control | Anti-RSV immunogens and methods of immunization |
| US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
-
2011
- 2011-07-07 CN CN201180033742.9A patent/CN103037898B/zh active Active
- 2011-07-07 WO PCT/US2011/043136 patent/WO2012006395A1/en not_active Ceased
- 2011-07-07 AU AU2011276251A patent/AU2011276251B2/en not_active Ceased
- 2011-07-07 DK DK11731610.9T patent/DK2590675T3/en active
- 2011-07-07 MX MX2012015030A patent/MX340796B/es active IP Right Grant
- 2011-07-07 BR BR112013000345-6A patent/BR112013000345B1/pt active IP Right Grant
- 2011-07-07 EP EP11731610.9A patent/EP2590675B1/en active Active
- 2011-07-07 RU RU2013101972A patent/RU2609661C2/ru active
- 2011-07-07 CA CA2799934A patent/CA2799934C/en active Active
- 2011-07-07 CN CN201610369657.4A patent/CN106008716B/zh active Active
- 2011-07-07 US US13/177,671 patent/US9487593B2/en active Active
- 2011-07-07 ES ES11731610.9T patent/ES2688993T3/es active Active
- 2011-07-07 JP JP2013518819A patent/JP5890407B2/ja active Active
-
2012
- 2012-10-28 IL IL222723A patent/IL222723B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012006395A1 (en) | 2012-01-12 |
| DK2590675T3 (en) | 2018-10-29 |
| US20120009254A1 (en) | 2012-01-12 |
| AU2011276251B2 (en) | 2015-02-05 |
| EP2590675A1 (en) | 2013-05-15 |
| CA2799934A1 (en) | 2012-01-12 |
| MX2012015030A (es) | 2013-06-13 |
| CA2799934C (en) | 2020-01-28 |
| CN106008716B (zh) | 2019-08-13 |
| IL222723A0 (en) | 2012-12-31 |
| JP5890407B2 (ja) | 2016-03-22 |
| US9487593B2 (en) | 2016-11-08 |
| RU2609661C2 (ru) | 2017-02-02 |
| CN103037898B (zh) | 2016-06-29 |
| AU2011276251A1 (en) | 2012-11-08 |
| IL222723B (en) | 2020-03-31 |
| CN106008716A (zh) | 2016-10-12 |
| BR112013000345A2 (pt) | 2016-05-31 |
| ES2688993T3 (es) | 2018-11-07 |
| EP2590675B1 (en) | 2018-08-29 |
| BR112013000345B1 (pt) | 2021-11-23 |
| CN103037898A (zh) | 2013-04-10 |
| JP2013535428A (ja) | 2013-09-12 |
| RU2013101972A (ru) | 2014-08-20 |
| AU2011276251A2 (en) | 2013-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340796B (es) | Composiciones y procedimientos antigenicos del virus respiratorio sincitial. | |
| HK1214962A1 (zh) | 流感病毒免疫原性组合物及其应用 | |
| WO2013006842A3 (en) | Self-replicating rna prime - protein boost vaccines | |
| WO2013184976A3 (en) | Compositions and methods for antigen-specific tolerance | |
| MX2025009589A (es) | Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| WO2014136064A3 (en) | Immunogenic fusion polypeptides | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| EP4382164A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| WO2011032161A8 (en) | Vaccines directed to langerhans cells | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| WO2012051211A3 (en) | Antigen delivery platforms | |
| WO2016105542A3 (en) | Nanoparticle compositions and methods for immunotherapy | |
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| MX2017001638A (es) | Molecula portadora para antigenos. | |
| EP4056198A3 (en) | Outer membrane vesicles | |
| WO2008033966A3 (en) | Alphavirus replicon particles matched to protein antigens as immunological adjuvants | |
| MX341775B (es) | Vectores para vacunas y metodos para potenciar respuestas inmunes. | |
| MX2014011712A (es) | Composiciones antigenas y procedimientos. | |
| WO2015179270A3 (en) | Combinatorial platform for the display of surface adjuvants and antigens | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| MX2014011713A (es) | Composiciones y procedimientos antipaludismo. | |
| MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
| WO2011100508A3 (en) | Methods and compositions related to glycoprotein-immunoglobulin fusions | |
| IN2014DN09445A (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |